Aug. 1 at 1:06 PM
Cantor⬆️
$APLS PT to
$40 from
$39, reiterated at an Overweight and said it thinks Empaveli C3G launch will go well.
$NVS AZN
$ALPMY $OCUL $EYPT REGN SRZN RHHBY
Cantor said in its note: "We reiterate Overweight rating on
$APLS as GA market is stabilizing and the launch in C3G/IC-MPGN is under way.
C3G patients and nephrologists face a decision on how to treat their C3 glomerulopathy diagnosis: by inhibiting C3 (with Empaveli) .... or by inhibiting "FaCtOr B" (woozy emoji). Never mind in addition to actually reducing C3 deposits, Empaveli also has meaningfully better efficacy, a broader label, and absence of a hyperlipidemia warning found in Fabhalta's label. Consequently, we think Empaveli C3G launch will go well."
